news, journals and articles from all over the world.
In a new study, Johns Hopkins researchers found that testing people for SARS-CoV-2 — the virus that causes COVID-19 — too early in the course of infection is likely to result in a false negative test, even though they may eventually test positive for the virus.
Cancer researchers at Children’s Hospital of Philadelphia (CHOP) have harnessed tools used for the development of cancer immunotherapies and adapted them to identify regions of the SARS-CoV-2 virus to target with a vaccine, employing the same approach used to elicit an immune response against cancer cells to stimulate an immune response against the virus. Using this strategy, the researchers believe a resulting vaccine would provide protection across the human population and drive a long-term immune response.
In a new study, published June 5, 2020, in the Journal of Experimental Medicine, scientists at La Jolla Institute for Immunology (LJI) shows that antibodies against JEV are “cross-reactive” and can also recognize Zika virus. Unfortunately, these antibodies can actually make Zika cases more severe.
A monthly media tip sheet of recent Fred Hutch research findings and other news.
A $1M gift from the John and Mary Tu Foundation is accelerating the efforts of UC San Diego translational research virologist Davey Smith to increase the number of people tested for COVID-19, as well as develop new ways to track and treat the virus. Smith and his team are studying how the disease spreads to better inform contact tracing, as well as leading clinical trials to test new drugs for treatment of COVID-19.
Notre Dame researchers create online tool to track development of coronavirus vaccines.
The internationally-renowned Gene Therapy Program at the University of Pennsylvania is joining the AAVCOVID vaccine program led by Massachusetts Eye and Ear and Massachusetts General Hospital (MGH), members of Mass General Brigham. AAVCOVID is a unique gene-based vaccine candidate designed to protect against SARS-CoV-2, the virus that causes COVID-19.
Researchers have received funding from the National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health, to screen and evaluate certain molecules known as adjuvants that may improve the ability of coronavirus vaccines to stimulate the immune system and generate appropriate responses necessary to protect the general population against the virus.
Dan Barouch, MD, PhD (Center for Virology and Vaccine Research, BIDMC) and colleagues reported today in Science two studies of laboratory monkeys that suggest antibodies produced during recovery from COVID-19 provide immunity from the virus, whether triggered by infection or vaccine.
To help accelerate discovery of therapeutic antibodies or antiviral drugs for SARS-CoV-2, the virus that causes COVID-19, Lawrence Livermore National Laboratory has launched a searchable data portal to share its COVID-19 research with scientists worldwide and the general public.
David Peabody, PhD, and Bryce Chackerian, PhD, are creating vaccines from particles that are the opposite of Trojan Horses: they look deadly on the outside but are harmless on the inside. Their virus-like particles may rouse the immune system into combatting COVID-19. The idea is to trick the body into believing it’s been infected with a microscopic foe.
Two LLNL biomedical scientists who have worked for more than eight years to develop a tularemia vaccine are part of a three-institution team that has been funded to bring their candidate vaccine to readiness for use
Medicine’s great triumph over polio holds out hope we can do the same for COVID-19, two researchers say.
Communities on Facebook that distrust establishment health guidance are more effective than government health agencies and other reliable health groups at reaching and engaging “undecided” individuals, according to a study published today in the journal Nature.
FACULTY Q&AANN ARBOR–In late April, the federal government announced Operation Warp Speed, an aggressive COVID-19 vaccine development program that aims to have at least 300 million doses of vaccine available in the United States by January. Jason Pogue, clinical professor of pharmacy, discusses the feasibility of this aggressive timetable.
Massachusetts Eye and Ear and Massachusetts General Hospital (MGH), members of Mass General Brigham, today announced progress towards the testing and development of an experimental vaccine called AAVCOVID, a novel gene-based vaccine candidate against SARS-CoV2, the virus that causes COVID-19. The AAVCOVID Vaccine Program is a unique, gene-based vaccine strategy that uses adeno-associated viral (AAV) vector, a clinically established gene transfer technology leveraging the properties of a harmless viral carrier.
Following the recent Coronavirus outbreak, almost three million people have been infected worldwide, whereas the death toll has already passed the 200,000 mark, according to official reports.
UNIVERSITY PARK, Pa. — Researchers are proposing a possible COVID-19 vaccine that could be good news for resisting current and future pandemics, as well as for the needle-phobic: inhalable vaccines. Scott Medina, Penn State assistant professor of biomedical engineering, is…
A new study by epidemiologists at the University of Notre Dame suggests social distancing measures at current levels in many states may need to be maintained until the summer to avoid a potentially deadly resurgence of the coronavirus.
UC San Diego nanoengineers received a Rapid Response Research (RAPID) grant from the National Science Foundation to develop—using a plant virus—a stable, easy to manufacture COVID-19 vaccine patch that can be shipped around the world and painlessly self-administered by patients.
To assist in the COVID-19 research effort, Lawrence Livermore National Laboratory, Penguin Computing and AMD have reached an agreement to upgrade the Lab’s unclassified, Penguin Computing-built Corona high performance computing (HPC) cluster with an in-kind contribution of cutting-edge AMD Instinct™ accelerators, expected to nearly double the peak performance of the machine.
The Weizmann Institute’s Prof. Roy Bar-Ziv has demonstrated the self-synthesis and self-assembly of a ribosomal subunit on the surface of a chip. The breakthrough could lead to novel types of vaccines, including for antibiotic-resistant bacteria, or to assembly lines to produce complex molecules for a range of industries.
Physicians and scientists at UC San Diego Health have launched a pair of serological tests that will look for novel coronavirus antibodies—evidence in persons tested that they have previously been infected by the viral cause of COVID-19, even if they never experienced tell-tale symptoms.
Supriya Munshaw, a senior lecturer at Johns Hopkins Carey Business School, offers insights on the likely time frame for a coronavirus vaccine, the steps involved in developing one, the most promising candidates currently in the labs of biotech companies, and why, years after the MERS and SARS outbreaks, a coronavirus vaccine still has not been produced.
In the race to identify solutions to the COVID-19 pandemic, researchers at the Department of Energy’s Oak Ridge National Laboratory are joining the fight by applying expertise in computational science, advanced manufacturing, data science and neutron science.
At Oak Ridge National Laboratory, it’s all-hands-on-deck for the world-leading experts in neutron scattering as they enter the fight against COVID-19. Researchers at the lab’s Spallation Neutron Source and High Flux Isotope Reactor have a plan of attack to unleash a full barrage of neutron capabilities in an ambitious set of experiments that will provide critical pieces of information about the virus’s biological structure and how it behaves.
In an article published recently in the journal Vaccine, two researchers in the Texas Tech University Department of Psychological Sciences suggest some people find vaccines risky because they overestimate the likelihood of negative events, particularly those that are rare.
Research is underway at The University of Texas at El Paso’s School of Pharmacy to develop vaccines and antiviral drugs to combat the novel coronavirus within 15 months to two years.
As clinical trials on potential vaccines and treatment drugs for the COVID-19 disease caused by the novel coronavirus get underway, researchers should strive for diversity in test subject selection, according to a leading expert on the topic. Marjorie A. Speers,…
The fastest recipe for worldwide access to a coronavirus vaccine may be to build upon on an existing vaccine with an already established manufacturing and supply chain.
Summaries of recent Fred Hutch research findings with links for additional background and media contacts.
An international collaboration of virologists at the University of Wisconsin–Madison and the vaccine companies FluGen and Bharat Biotech has begun the development and testing of a unique vaccine against COVID-19 called CoroFlu.
A potential COVID-19 vaccine, delivered by microscopic needles, produces antibodies specific to the virus when tested in mice. This is the first peer-reviewed paper describing a COVID-19 vaccine candidate. The next step is a human clinical trial.
Vaccine expert working on developing covid-19 vaccine, sees major differences between Covid-19 and SARS
Though COVID-19 so far appears to be largely sparing children, researchers are cautioning that it is critical to understand how the virus affects kids to model the pandemic accurately, limit the disease’s spread and ensure the youngest patients get the care they need.
redirect to event registration Newswise Live Expert Panel discussion of unique angles to the COVID-19 outbreak of interest to the public and the media, including public health, testing, business and financial markets, 2020 elections, and more. Experts from institutions…
MOSCOW (MIPT) — The atomic structure of the novel coronavirus envelope has explained why it is exceptionally contagious. Its structural features make it much easier for the Chinese coronavirus to bind to target receptors, compared with the previously known SARS…
THE SITUATIONVaccine acceptance is a crucial public health issue, which has been exacerbated by the use of social media to spread content expressing vaccine hesitancy. Studies have shown that social media can provide new information regarding the dynamics of vaccine…
By figuring out how a common virus hides from the immune system, scientists have identified a potential vaccine to prevent sometimes deadly respiratory infections in humans.
Wistar announces today that they are part of a team to develop a vaccine against the recently emerged strain of coronavirus (2019-nCoV) that has infected hundreds in China and other countries, including the U.S., and resulted in numerous deaths to date. Wistar is part of a collaboration funded by the Coalition for Epidemic Preparedness Innovations (CEPI).
The results of the B Part of It study – the largest meningococcal B herd immunity study ever conducted – are published today in the New England Journal of Medicine.
T. Patrick Hill, a Rutgers-New Brunswick professor of ethics and law, is available to discuss a New Jersey bill that would eliminate religion as a reason not to vaccinate public schoolchildren. Lawmakers are expected to vote Monday afternoon. “The vaccination…
An isoelectric point is a common way to characterize viruses. However, it’s not easy. To improve manufacturing for vaccines and gene therapy, a Michigan Tech team uses surface charge to determine the isoelectric point of different viruses. Specifically, they use a single-particle method with atomic force microscopy (AFM).
Weizmann Institute scientists created a decoy molecule that successfully recruits the immune system to fight arenaviruses. It also appears to be heat-resistant and stable, meaning it could be delivered to the remote areas where these diseases are endemic.
Researchers at the Icahn School of Medicine at Mount Sinai have discovered a way to move precision immunotherapy forward by using genomics to inform immunotherapy for multiple myeloma, a blood cancer, according to a study published in Clinical Cancer Research, a journal of the American Association for Cancer Research, in December.
Naturally occurring chemicals in the global food supply are known to pose a burden on worldwide health. New studies have found that a certain foodborne toxin, in addition to its known health effects,, is also linked to vaccine resistance, and for the first time the global burden of disease from foodborne arsenic, lead, cadmium, and methyl mercury has been quantified.. The Society for Risk Analysis (SRA) will present new studies as part of its Global Disease Burden Caused by Foodborne Chemicals and Toxins symposium on Monday, Dec. 9 from 1:30-3:00 p.m. as part of its 2019 Annual Meeting at the Crystal Gateway Marriott in Arlington, Virginia. This symposium will provide updates to a 2015 World Health Organization (WHO) publication which analyzed the disease burdens caused by these toxins.
Peanut allergies could become a thing of the past as breakthrough research from the University of South Australia develops a radically novel vaccination that’s poised to cure the potentially life threatening condition.
Virologist Eric Cohen and his team have identified a way to thwart HIV infection at its very early stages.
News wise on Dengue related news. An experimental dengue vaccine has shown promising early results in a large, multicountry trial, but critical questions remain about its effectiveness and safety. Still unclear, for example, is whether the vaccine—which had an efficacy…
Study shows measles wipes out 20 to 50 percent of antibodies against an array of viruses and bacteria, depleting a child’s previous immunity
Measles-ravaged immune system must “relearn” how to protect the body against infections
Study details mechanism and scope of this measles-induced “immune amnesia”
Findings underscore importance of measles vaccination, suggesting those infected with measles may benefit from booster shots of all previous childhood vaccines
English
Arabic
Chinese (Simplified)
Dutch
Esperanto
French
German
Greek
Italian
Japanese
Korean
Portuguese
Russian
Spanish
Urdu